GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction.
other
Where this comes from
- Record sourced from PubMed, PMID 40466625.
- Also identified by DOI 10.1016/j.cmet.2025.05.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With the rising prevalence of T2D worldwide, peripheral artery disease (PAD) now affects >230 million individuals globally. In the recent STRIDE trial, Bonaca et al.<sup>1</sup> demonstrated that semaglutide improved walking capacity and hemodynamic parameters and slowed PAD progression in patients with T2D. These results reveal an unanticipated vasculoprotective benefit of GLP-1RAs.
Medical subject headings
- Peripheral Arterial Disease
- Diabetes Mellitus, Type 2